Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.
Grey
Andrew
A
O'Sullivan
Susannah
S
Reid
Ian R
IR
Browett
Peter
P
D000328:Adult; D001549:Benzamides; D015415:Biomarkers / Q000378:metabolism; D016723:Bone Remodeling / Q000187:drug effects*; D002118:Calcium / Q000378:metabolism*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000139:chemically induced*; D017674:Hypophosphatemia / Q000139:chemically induced*; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
D001549:Benzamides; D015415:Biomarkers; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D002118:Calcium